Registry analysis demonstrates similar safety profiles and drug persistence in rheumatoid arthritis and spondyloarthritis, indicating comparable real-world therapeutic viability.
To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).
No takes yet. Share an insight, caveat, or question.
Hernández‐Cruz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: